Succinylacetone

Succinylacetone (CAS No.: 51568-18-4) is an endogenous metabolite derived from the tyrosine catabolic pathway and is widely recognized as a potent inhibitor of heme biosynthesis through its selective inhibition of δ-aminolevulinic acid dehydratase, a key enzyme in the porphyrin synthesis pathway. By disrupting this enzymatic step, succinylacetone interferes with porphyrin metabolism and leads to reduced heme production, thereby serving as a valuable biochemical tool for studying the regulation of heme biosynthesis and associated metabolic networks. It is also an abnormal metabolite that accumulates in hereditary tyrosinemia type I due to deficiency of fumarylacetoacetate hydrolase, making it a clinically relevant biomarker and a mechanistic contributor to disease pathology. In vitro studies demonstrate that succinylacetone exhibits inhibitory activity in the nanomolar to micromolar range and can suppress the proliferation of certain erythroid cell lines at higher concentrations, reflecting its impact on cellular heme availability. In vivo, administration in experimental models alters systemic heme levels and affects vascular and metabolic functions, supporting its use in disease modeling. Consequently, succinylacetone is extensively employed in biochemical and pharmacological research to investigate porphyrin-related disorders, establish models of tyrosinemia, and explore therapeutic strategies targeting heme biosynthesis, with experimental concentrations or dosing regimens adjusted according to specific study designs.